Clinical study on individualized medication of tacrolimus after liver transplantation guided by CYP3A5 gene polymorphism for hepatocellular carcinoma

Abstract

Abstract: Objective: To evaluate the safety and efficacy based on CYP3A5 gene polymorphisms in guiding the individualized tacrolimus therapy after liver transplantation for hepatocellular carcinoma. Methods: Clinical data of 120 patients with primary hepatocellular carcinoma were analyzed who underwent orthotopic liver transplantation from January 2018 to December 2019. According to whether the donor and recipient CYP3A5 gene was detected before operation, they were divided into individualized medication group and conventional medication group. The initial dose of tacrolimus was determined according to CYP3A5 genotype and previous experience in the two groups. The recovery rates of liver function at 14, 21, 28 days and 3, 6, 9, 12 months after operation were observed. The incidence of acute rejection, acute kidney injury, neurological symptoms, infection, de novo hypertension, de novo diabetes and the overall survival rate were recorded. Results: The differences of recovery rate of liver function between the two groups of recipients at 14 days and 21 days after was statistically significant (all P<0.05). There was no significant difference in the incidence of complications and overall 1-year and 2-year survival rates between the two groups (P> 0.05). Conclusion: It is safe to guide individualized tacrolimus after liver transplantation according to CYP3A5 gene polymorphism and beneficial to long-term survival for hepatocellular carcinoma recipients.

Key words: Hepatocellular carcinoma, Liver transplantation, Tacrolimus, Individualized medication

Jiang Tao, Pan Fei, Chen Qing, Huang Jincan, He Qiang, Lang Ren. Clinical study on individualized medication of tacrolimus after liver transplantation guided by CYP3A5 gene polymorphism for hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2021, 8(3): 8-11.

References

[1] YANG N, EKANEM NR, SAKYI CA, et al.Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics[J]. Adv Drug Deliv Rev, 2015, 81: 62-74.
[2] VIVAREIII M,CUCCHETTI A,LA BARBA G,et al.Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J].AnnSurg, 2008, 248(5): 857-862.
[3] JAIN A, DOPPALAPUDI S, DOMB AJ, et al.Tacrolimus and curcumin co-loaded liposphere gel: synergistic combination towards management of psoriasis[J]. J Control Release, 2016,243: 132-145.
[4] KUYPERS DR."What do we know about tacrolimus pharmacogenetics in transplant recipients?"[J]. Pharmacogenomics, 2018,19(7): 593-597.
[5] DEBETTE-GRATIEN M, WOILLARD JB, PICARD N, et al.Influence of donor and recipient CYP3A4, CYP3A5, and ABCB1 genotypes on clinical outcomes and nephrotoxicity in liver transplant recipients[J]. Transplantation, 2016, 100(10): 2129-2137.
[6] WANG YQ, WANG CH, ZHANG JH.Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta- analysis[J]. Thromb Res, 2016, 147: 1-6.
[7] 高慧儿,王姗,闫美玲,等.IATDMCT他克莫司个体化治疗的TDM共识(2019版)报告解读[J]. 实用器官移植电子杂志, 2020, 8(1): 1-8.
[8] 危荣沥,徐骁.肝细胞癌肝移植分子分型与精准治疗[J].实用器官移植电子杂志,2019,7(1): 62.
[9] MALUCCIO M,SHARMA V,LAGMANa M, et al.Tacrolimus enhances transforming growthfactor-beta1 expression and promotes tumor progression[J]. Transplantation, 2003, 76(3): 597-602.
[10] SUTHANTHIRAN M, HOJO M, MALUCCIO M, et al.Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy[J].Trans Am Clin Climatol Assoc, 2009,120: 369-388.
[11] RODRÍGUEZ-PERÁLVAREZ M, TSOCHATZIS E, NAVEAS MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(6): 1193-1199.
[12] WEI Q, GAO F, ZHUANG R, et al.A national report from China Liver Transplant Registry: steroid avoidance after liver transplantation for hepatocellular carcinoma[J]. Chin J Cancer Res, 2017, 29(5): 426-437.
[13] 中国医师协会器官移植医师分会,中华医学会器官移植学分会.中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志,2019,35(2):275-280.
[14] GUBA M, VON BREITENBUCH P, STEINBAUER M, et al.Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor[J]. Nat Med, 2002, 8(2): 128-135.
[15] WANG Z, ZHOU J, FAN J, et al.Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma[J]. Cancer Res Clin Oncol, 2009,135(5): 715-722.
[16] CAMPAGNE O, MAGER DE, TORNATORE KM.Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities?[J]. J Clin Pharmacol, 2019, 59(3): 309-325.
[17] CZERWIŃSKI M, AMUNOM I, PIRYATINSKY V, et al. Direct and cytokine-mediated effects of albumin-fused growth hormone, TV-1106, on CYP enzyme expression in human hepatocytes in vitro[J]. Pharmacol Res Perspect, 2018, 16(3): e00397.
[18] BERGER FA, MULDER MB, TEN BOSCH-DIJKSMAN W, et al. Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose[J]. Br J Clin Pharmacol, 2019, 85(8): 1852-1854.
[19] JI E, KIM MG, OH JM.CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation[J]. Ther Clin Risk Manag, 2018, 14: 2119-2126.
[20] PASTERNAK AL, ZHANG L, HERTZ DL.CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration[J]. Pharmacogenomics, 2018, 19(6): 563-576.
[21] HENDERSON LM, CLAW KG, WOODAHL EL, et al.P450 pharmacogenetics in Indigenous North American populations[J]. J Pers Med, 2018, 8(1): E9.
[22] 王璐, 李宁, 卢实春, 等. 供受体CYP3A5基因多态性对成人肝移植术后他克莫司浓度/剂量比的影响[J]. 实用器官移植电子杂志, 2013, 1(2): 88-94.
[23] MURAKI Y, MIZUNO S, NAKATANI K, et al.Monitoring of peripheral blood cluster of differentiation 4+ adenosine triphosphate activity and CYP3A5 genotype to determine the pharmacokinetics, clinical effects and complications of tacrolimus in patients with autoimmune diseases[J]. Exp Ther Med, 2018, 15(1): 532-538.
[24] DENG R, LIAO Y, LI Y, et al.Association of CYP3A5, CYP2C8, and ABCB1 polymorphisms with early renal injury in Chinese liver transplant recipients receiving tacrolimus[J]. Transplant Proc, 2018, 50(10): 3258-3265.
[25] LIU Y, ZHANG T, ZHANG X, et al.A new donors' CYP3A5 and recipients' CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients[J]. Oncotarget, 2017, 8(41): 70250-70261.
[26] 何莉,栗光明,林栋栋,等.根据CYP3A5*1基因多态性指导肝移植术后他克莫司个体化用药的前瞻性对照研究[J].器官移植, 2020,11(4):455-460.